Drug management in chronic rhinosinusitis: identification of the needs
Authors Jean-Baptiste HPJ Watelet, Philippe H Eloy, Paul B van Cauwenberge
Published 15 March 2007 Volume 2007:3(1) Pages 47—57
Jean-Baptiste HPJ Watelet1, Philippe H Eloy2, Paul B van Cauwenberge1
1Department of Otorhinolaryngology, University of Ghent, Ghent, Belgium; 2Department of Otorhinolaryngology, CHU Mont-Godinne, Université Catholique de Louvain, Yvoir, Belgium
Abstract: Chronic rhinosinusitis (CRS) is a group of multifactorial diseases characterized by inflammation of the mucosa of the nose and paranasal sinuses with a history of at least 12 weeks of persistent symptoms despite maximal medical therapy. The precise role played by infection and immunoglobin E (IgE)-mediated hypersensitivity remains unclear. Diagnosis of CRS is based upon medical history, nasal endoscopy and computed tomography scan of the sinuses. The CRS with polyps visible in the middle meatus must be distinguished from the CRS without polyps. Based on the current knowledge about the pathogenesis of CRS, it is admitted that an optimal medical treatment must consider all favorizing factors and control efficaciously the inflammation process. In case of failure of medical treatment, endoscopic sinus surgery should be proposed. However, some well-validated data and scientific evidences are missing, even for the most frequently used medications. After a review of the actual definitions and classifications, a short description of the current knowledge about pathogenesis of CRS is provided in order to justify the actual therapeutic rationales and identify the needs for an effective treatment of CRS.
Keywords: rhinosinusitis, pathogenesis, diagnosis, management, guidelines